Windlas Biotech LimitedQ1 FY27 Results & Financial Update
Windlas Biotech Limited: Q1 FY27 standalone results and company financials – revenue ₹248.10 Cr, PAT ₹17.65 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceReported figures and period changes.Changes compare like-for-like reported periods where available.
Find an answer
Ask this result
Chart · Market context
Windlas Biotech price & chart
Market price₹1,030.70
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Windlas Biotech Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Windlas Biotech delivered its 14th consecutive quarter of record revenue in Q1 FY27, reporting revenue from operations of Rs 248.10 crore, representing an 18.09% increase year-on-year compared to Rs 210.09 crore in Q1 FY26 and a sequential growth from Rs 238.50 crore in Q4 FY26.
The broader Indian Pharmaceutical Market registered a modest volume growth of 3.4% during the quarter, highlighting Windlas Biotech's outperformance driven by customer expansion, deeper client engagement, and new product introductions.
The core Generic Formulations CDMO vertical remained the primary growth engine, expanding by 29% year-on-year to Rs 207 crore and accounting for approximately 84% of total revenue. Conversely, the Trade Generics & Institutional vertical contracted by 32% year-on-year to Rs 30 crore due to the discontinuation of certain codeine-based products.
The Exports vertical achieved strong momentum, surging 79% year-on-year to Rs 11 crore, representing approximately 4% of total revenue as the company expands its footprint across emerging and semi-regulated international markets.
During the quarter, the company completed a share buyback of Rs 47 crore through the tender offer route without promoter participation, reducing the total paid-up equity shares, and subsequently declared a dividend of Rs 6.30 per equity share for FY26, amounting to Rs 13 crore.
01 · Business model
What does Windlas Biotech do?
Windlas Biotech Limited operates as a leading player in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India. The company provides comprehensive services ranging from product discovery, product development, licensing, and commercial manufacturing of generic products.
The business model covers three core verticals: Generic Formulations CDMO, Trade Generics & Institutional, and Exports. The company owns the intellectual property and formulation technology for almost all the products it supplies, serving marquee domestic and multinational pharmaceutical clients.
With manufacturing plants located primarily in Dehradun, Uttarakhand, the company produces a wide array of dosage forms including solid oral solids (tablets and capsules), liquid bottles, sachets, pouch packaging, and specialized injectables like ampoules, liquid vials, and lyophilized vials.
02 · Historical context
What shaped the business before this quarter
Pursuant to a Board resolution in February 2026 and filing with the Delaware Division of Corporations, Windlas Inc., USA (a wholly owned non-operating subsidiary) was dissolved effective March 31, 2026, leading to standalone financial reporting from April 1, 2026 onward.
The company expanded its technological and manufacturing capabilities over recent years by scaling up Dehradun facilities, commissioning the Plant-5 injectable facility in FY25, and initiating capex for Plant-6 to boost oral solid dosage capacity.
03 · Financial snapshot
Current quarter vs the two useful baselines
| Metric | Q1 FY27 | Year-ago | Previous quarter |
|---|---|---|---|
| Revenue from operations | ₹248.10 Cr | ₹210.09 Cr | ₹238.50 Cr |
| Total income | ₹253.21 Cr | ₹215.33 Cr | ₹242.90 Cr |
| Profit before tax | ₹22.94 Cr | ₹23.26 Cr | ₹20.16 Cr |
| Profit after tax | ₹17.65 Cr | ₹17.67 Cr | ₹16.02 Cr |
| EPS | ₹8.46 | ₹8.43 | ₹7.60 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
CDMO revenue expanded 29% year-on-year to Rs 207 crore in Q1 FY27, supported by customer acquisition, deeper engagement with existing clients, and new product launches.
Exports recorded a 79% year-on-year growth to reach Rs 11 crore, driven by dossier registrations and product shipments across emerging and semi-regulated international markets.
Trade Generics & Institutional revenue declined 32% year-on-year to Rs 30 crore, impacted by the discontinuation of codeine-based products, which management expects to progressively bridge with new launches and replacements.
What drove margins
The company recorded non-cash employee stock option plan (ESOP) expenses of Rs 7.16 crore during Q1 FY27, impacting reported profitability metrics while operating cash flows remained unaffected.
Excluding non-cash ESOP charges, adjusted EBITDA grew 26% year-on-year to Rs 34 crore with a margin of 13.6% (compared to 12.8% in Q1 FY26), reflecting improved operating leverage.
05 · Demand, customers & order book
Where demand is coming from
Windlas serves hundreds of customers, including leading domestic pharmaceutical companies and multinational corporations, while maintaining a diversified portfolio to mitigate client concentration risk.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Contributed approximately 84% of total revenue in Q1 FY27, generating Rs 207 crore with a 29% year-on-year growth rate.
Contributed approximately 12% of total revenue, generating Rs 30 crore with a 32% year-on-year decrease due to codeine-based product discontinuations.
Contributed approximately 4% of total revenue, generating Rs 11 crore, marking a 79% year-on-year expansion.
Geography and market mix
Domestic formulations and CDMO operations dominate revenue generation, while international exports extend across emerging and semi-regulated markets with products exported to multiple countries.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The company's specialized manufacturing facilities, including oral solid dosage plants and the recently operationalized Plant-5 injectable facility, continue to drive scalable growth and support rising production volumes.
Projects, capex and execution
The company is on track for the commercialization of Plant-6 in H1 FY27, which will further strengthen manufacturing capacity for oral solid dosages and support future growth opportunities.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Strategic focus remains centered on expanding offerings into complex generics, injectables, and novel dosage forms such as medicated chews and sustained-release formulations.
09 · Reported developments
What changed operationally
Achieved its 14th consecutive quarter of record revenue, reaching Rs 248.10 crore in Q1 FY27, up 18.09% year-on-year.
Adjusted EBITDA grew 26% year-on-year to Rs 34 crore and adjusted PAT grew 37% year-on-year to Rs 25 crore, excluding non-cash ESOP charges.
10 · Pressure points & risks
What is not going smoothly
Trade Generics & Institutional revenue declined 32% year-on-year due to the discontinuation of codeine-based products.
11 · Items worth noticing
The line items that can distort a quick read
Recorded non-cash employee share-based payment expenses of Rs 71.62 million (Rs 7.16 crore) for the quarter ended June 30, 2026.
12 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
During Q1 FY27, the company completed a share buyback of Rs 47 crore via tender offer without promoter participation and paid out FY26 dividends of Rs 13 crore (Rs 6.30 per share).
Capital allocation & funding
The company maintains a strong financial position with robust liquidity and disciplined capital allocation to support ongoing expansion initiatives.
13 · Management guidance & targets
What management is targeting from here
Management expressed confidence in the underlying growth opportunities across all three business verticals, aiming to bridge trade generic gaps through portfolio replacements and new product introductions.
14 · Beyond the numbers
What changed beyond the numbers
Reported update
Share Buyback Completion
The company successfully completed a Rs 47 crore share buyback through the tender offer route without promoter participation, extinguishing 470,000 equity shares.
Reported update
Annual Dividend Payout
Shareholders at the Annual General Meeting approved a dividend of Rs 6.30 per equity share for FY26, resulting in an aggregate payout of Rs 130.01 million paid on July 31, 2026.
15 · Previous-quarter changes
What changed since the previous quarter
Following the dissolution of its US subsidiary Windlas Inc. effective March 31, 2026, the company transitioned from consolidated reporting to standalone financial statements starting April 1, 2026.
16 · Key Q&A
The quarter, answered directly
What does Windlas Biotech do?
Windlas Biotech Limited operates as a leading player in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India. The company provides comprehensive services ranging from product discovery, product development, licensing, and commercial manufacturing of generic products.
What is the clearest takeaway from Q1 FY27?
Windlas Biotech delivered its 14th consecutive quarter of record revenue in Q1 FY27, reporting revenue from operations of Rs 248.10 crore, representing an 18.09% increase year-on-year compared to Rs 210.09 crore in Q1 FY26 and a sequential growth from Rs 238.50 crore in Q4 FY26.
What drove revenue or demand?
CDMO revenue expanded 29% year-on-year to Rs 207 crore in Q1 FY27, supported by customer acquisition, deeper engagement with existing clients, and new product launches.
What mattered most for margins or profitability?
The company recorded non-cash employee stock option plan (ESOP) expenses of Rs 7.16 crore during Q1 FY27, impacting reported profitability metrics while operating cash flows remained unaffected.
What changed operationally beyond the headline numbers?
The company's specialized manufacturing facilities, including oral solid dosage plants and the recently operationalized Plant-5 injectable facility, continue to drive scalable growth and support rising production volumes.
What is management guiding or targeting from here?
Management expressed confidence in the underlying growth opportunities across all three business verticals, aiming to bridge trade generic gaps through portfolio replacements and new product introductions.
17 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
18 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Trade Generics Recovery: Track new product launches and portfolio replacements aimed at bridging the revenue gap in the Trade Generics & Institutional vertical.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.